Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread Formerly Known as No Rest For The Wicked -- Ignore unavailable to you. Want to Upgrade?

To: Devil's Advocate who wrote (3316)	12/18/1998 10:04:00 AM
From: Street Walker	Respond to of 90042

CEGE --- read this Cell Genesys CEGE announces the signing of a worldwide collaboration with the pharmaceutical division of Japan Tobacco Inc. (JT) for selected product candidates from the company's GVAX™ cancer vaccine program. CEGE could receive up to $27.5 million in research and development funding in the first three years, and approximately $80 million in milestone payments if JT continues in the collaboration through the regulatory approvals of the two products according to the release. The agreement provides for committed payments to Cell Genesys of $12.7 million due at signature and a first anniversary payment of $2.5 million and provides for loans of up to $30 million to Cell Genesys for Phase III development costs if JT continues in the collaboration into Phase III trials. CEGE gapping 5 biz.yahoo.com Excerp taken from: daytraders.org